GOSS Gossamer Bio Inc

Raymond James analyst Steven Seedhouse maintained a Buy rating on Gossamer Bio (GOSS - Research Report) today and set a price target of $5.00. The company's shares closed yesterday at $2.36.According to TipRanks, Seedhouse is a 3-star analyst with an average return of 1.9% and a 40.66% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Apellis Pharmaceuticals.In addition to Raymond James, Gossamer Bio also received a Buy from SVB Securities's Joseph Schwartz in a report issued today. However, on the same day, Barclays downgraded Gossamer Bio (NASDAQ: GOSS) to a Hold.
https://www.tipranks.com/news/blurbs/gossamer-bio-goss-gets-a-buy-from-raymond-james?utm_source=advfn.com&utm_medium=referral